Ocular Drug Delivery System Market Is Expected to Total US$ 27.82 Billion By the End Of 2031


Market Insights on Ocular Drug Delivery System covering sales outlook, demand forecast & up-to-date key trends

FMI54

As per a study by Future Market Insight (FMI), the global ocular drug delivery system market size is likely to surpass a valuation of US$ 14.47 billion by the end of 2021, growing at a CAGR of 6.8% between 2021 and 2031. By 2031, ocular drug delivery systems sales are expected to reach US$ 27.82 billion.

The primary factor driving ocular drug delivery systems adoption is the increasing incidence of ophthalmic diseases and injuries. In the U.S., around 2,000 workers requires medical assistance due job-related eye injuries every day, according to a report published by the National Institute for Occupational Safety and Health (NIOSH).

Also, over 12 million people aged above 40 years have vision impairment in the country. Thus, the demand for effective treatment to curb the rising incidence of ophthalmic diseases and injuries is expected to create growth opportunities for the market. 

Ocular drug delivery system companies are aiming at developing new products to enhance the potency of spatiotemporal drug administration. For instance, pSivida Corp. is focusing on launching its new product named, Durasert, a uveitis implant for the treatment of posterior uneitis infection. These ongoing improvements in treatment for ophthalmic diseases will favor the market growth over the assessment period.

"Increasing adoption of novel drug delivery technologies such as micro- and nanoparticles and implantable devices for posterior eye therapy is anticipated to open the floodgates for advanced ocular drug treatments," says the FMI analyst. 

To remain ‘ahead’ of your competitors, request a report sample @

https://www.futuremarketinsights.com/reports/sample/rep-gb-6027

Key Takeaways

  • The U.S. is leading the ocular drug delivery system market in North America with a market share of 86% in the region.
  • With improvements in drug development pipelines, the U.K. is expected to account for over 24% of the market share in Europe by the end of 2031.
  • The market in Germany is estimated to grow at a CAGR of 4.6% making it the second leading market in the U.K.
  • Owing to the growing healthcare spending, Japan is projected to account for over 52% of the sales in East Asia by 2021.
  • Ophthalmic solution is likely to remain the dominant segment during the forecast period and hold a market share of nearly 60% by the end of 2031.

Key Drivers

  • Increasing incidence of ophthalmic diseases and injuries will fuel the demand for the ocular drug delivery system market.
  • Favorable reimbursement policies will drive the growth of the market.
  • Rising demand for targeted drug delivery techniques will bolster the market growth.
  • Ongoing advancement in drug delivery treatment will spur the demand for the ocular drug delivery system market.

Key Restraints

  • High cost and complexities associated with the treatment is restraining the market growth.
  • Low bioavailability of drugs for conventional ocular therapies is hampering the growth of the ocular drug delivery system market.
  • The discomfort such as irritation, excessive lachrymation, and drug dilution occurring post the treatment is negatively impacting the market growth.

Competitive Landscape

Leading ocular drug delivery system manufacturers are focusing on engaging in strategic collaborations and developing new products to maintain their lead in the market. For instance,

  • Clear side Biomedical, the U.S. based company, announced its strategic collaboration with EyeKor in March 2017, to support Clearside's clinical development efforts.
  • In October, 2020, AffaMed Therapeutics and Ocular Therapeutix™ announced collaboration and license agreement for OTX-TIC and DEXTENZA® in Asia.

Get a Customized Scope to Match Your Need Ask an Expert – Ask from an expert @

https://www.futuremarketinsights.com/ask-question/rep-gb-6027

Some of the leading companies operating in the ocular drug delivery system market profiled by FMI are:

  • Graybug Vision Inc.
  • Allergan Plc.
  • Ocular Therapeutix, Inc.
  • Alimera Sciences
  • pSivida
  • Santen Pharmaceutical Co., Ltd
  • Taiwan Liposome Company Ltd.
  • Envisia Therapeutics
  • Eyegate Pharma
  • Valeant Pharmaceuticals International, Inc
  • Vision Ophthalmology Group GmbH
  • Clearside Biomedical
  • URSAPHARM Arzneimittel GmbH

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2,

Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

LinkedInTwitterBlogs

About Future Market Insights

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce)

Contact Information

Future Market Insights

Christiana Corporate, 200 Continental Drive
Suite 401, Newark, Delaware
19713
UK
Phone : +1-845-579-5705
View website

Published in

Health

Published on

Jun 30, 2022

Social Links

Twitter page of PRnob.com LinkedIn page of PRnob.com